Inogen Appoints Stanislav Glezer as Chief Technology Officer
October 12 2021 - 4:05PM
Business Wire
Inogen, Inc. (NASDAQ: INGN), (“Inogen” or “the Company”), a
medical technology company offering innovative respiratory products
for use in the homecare setting, today announced that Stanislav
Glezer, MD has been appointed to the role of Chief Technology
Officer responsible for R&D and Engineering, Medical Affairs,
and Regulatory Affairs. Mr. Glezer will remain an Executive Vice
President of the Company.
Dr. Glezer joined Inogen in June 2021 as Executive Vice
President and Chief Medical Officer bringing over 27 years of
experience, including expertise in the development and
commercialization of combination drug device innovations, clinical
development, medical and regulatory affairs as well as market
access. His leadership roles span a variety of medical technology
and biotechnology firms, including Becton, Dickinson and Company,
Adocia S.A., Novo Nordisk, Inc., and Sanofi S.A.
Inogen also announced that Brenton Taylor, Executive Vice
President, Engineering, will be leaving the Company after a
transition period ending April 1, 2022.
“Since joining Inogen as Chief Medical Officer earlier this
year, Stan has made a significant impact in helping us instill
clinically-informed discipline in innovation, product development
practices and go-to-market strategy. In this new role, Stan’s deep
background in clinical research, success in developing,
commercializing, and securing access for new innovations will be
vital as we drive the next phase of growth and shareholder value
creation,” said Nabil Shabshab, President and Chief Executive
Officer of Inogen. “On behalf of all of us at Inogen, I want to
thank Brenton for the instrumental role he played in founding
Inogen and being an important part of its growth journey so far. We
look forward to working with him on a seamless transition of his
duties over the next several months and wish him well in his future
endeavors.”
Dr. Glezer said, “Since joining Inogen, my view of the
tremendous opportunity that lies ahead to develop products that
meaningfully improve patient outcomes has only deepened. In this
expanded role, I look forward to continuing our efforts to develop
an integrated innovation strategy and agenda as well as to expand
our collaboration with health care practitioners and technology
experts to develop clinical solutions that support patients,
enhance our market position and drive value for shareholders.”
Mr. Taylor commented: “It has been a privilege to work with such
a talented and dedicated team over the past 20 years to design
products that have improved so many lives around the world. As part
of Inogen’s founding team I am proud that Inogen has become an
industry leader and I look forward to following Inogen’s continued
evolution and success.”
Inogen has used, and intends to continue to use, its Investor
Relations website, http://investor.inogen.com/, as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD. For more
information, visit http://investor.inogen.com/.
About Inogen
We are a medical technology company offering innovative
respiratory products for use in the homecare setting. We primarily
develop, manufacture and market innovative portable oxygen
concentrators used to deliver supplemental long-term oxygen therapy
to patients suffering from chronic respiratory conditions.
For more information, please visit www.inogen.com.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, among others, statements with respect to the
announced management and organizational changes, statements
concerning or implying Inogen’s future financial performance,
trends and opportunities affecting Inogen, and the ability of
management personnel to contribute to the development,
commercialization, and access for new innovations of Inogen’s
products and technologies, expand and grow its business, and
increase value for its stockholders. Any statements contained in
this communication that are not statements of historical fact may
be deemed to be forward-looking statements. Words such as
“believes,” “anticipates,” “plans,” “expects,” “will,” “intends,”
“potential,” “possible,” and similar expressions are intended to
identify forward-looking statements. Forward-looking statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from currently anticipated results,
including but not limited to, risks related to its announced
management and organizational changes, risks arising from the
possibility that Inogen will not realize anticipated revenue; risks
related to the Company’s supply chain and limited availability of
semiconductor chips used in its batteries and POCs or cost
inflation for such components; the risks related to the COVID-19
pandemic; the impact of changes in reimbursement rates and
reimbursement and regulatory policies; the possible loss of key
employees, customers, or suppliers; intellectual property risks if
Inogen is unable to secure and maintain patent or other
intellectual property protection for the intellectual property used
in its products. In addition, Inogen's business is subject to
numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of its products;
competition; its sales, marketing and distribution capabilities;
its planned sales, marketing, and research and development
activities; interruptions or delays in the supply of components or
materials for, or manufacturing of, its products; seasonal
variations; unanticipated increases in costs or expenses; and risks
associated with international operations. Information on these and
additional risks, uncertainties, and other information affecting
Inogen’s business operating results are contained in its Quarterly
Report on Form 10-Q for the period ended June 30, 2021, and in its
other filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. Inogen
disclaims any obligation to update these forward-looking statements
except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211012006091/en/
Investor Relations: Ali Bauerlein ir@inogen.net
Media: George Parr media@inogen.net
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inogen (NASDAQ:INGN)
Historical Stock Chart
From Apr 2023 to Apr 2024